Association between anti-citrullinated alpha enolase antibodies and clinical features in a cohort of patients with rheumatoid arthritis: a pilot study

  • A. Alunno Rheumatology Unit, Department of Medicine, University of Perugia, Italy.
  • O. Bistoni Rheumatology Unit, Department of Medicine, University of Perugia, Italy.
  • F. Pratesi Clinical Immunology and Allergy Unit, Department of Clinical and Experimental Medicine, University of Pisa, Italy.
  • F. Topini Rheumatology Unit, Department of Medicine, University of Perugia, Italy.
  • I. Puxeddu Clinical Immunology and Allergy Unit, Department of Clinical and Experimental Medicine, University of Pisa, Italy.
  • V. Valentini Rheumatology Unit, Department of Medicine, University of Perugia, Italy.
  • G. Cafaro Rheumatology Unit, Department of Medicine, University of Perugia, Italy.
  • E. Bartoloni Rheumatology Unit, Department of Medicine, University of Perugia, Italy.
  • P. Migliorini Clinical Immunology and Allergy Unit, Department of Clinical and Experimental Medicine, University of Pisa, Italy.
  • R. Gerli | roberto.gerli@unipg.it Rheumatology Unit, Department of Medicine, University of Perugia, Italy.

Abstract

In recent years several antibodies against citrullinated peptides (ACPAs) have been identified in patients with rheumatoid arthritis (RA) and their pathogenic, diagnostic and prognostic significance is under intense investigation. Among ACPAs, those targeting citrullinated alpha enolase (anti-CEP1) have been identified in RA but data about their ability to predict the development of erosive disease are conflicting. Furthermore, no data are currently available concerning their possible association with extra-articular manifestations (EAMs) in RA. The aim of this study was to investigate the prevalence and significance of anti-CEP1 from a prognostic point of view. In this pilot study we confirmed that anti-CEP1 Abs are associated with higher prevalence of bone erosions, but we also provided the first evidence of an association between anti-CEP1 Abs and RA interstitial lung disease (ILD). These results provide the basis to investigate the association between anti-CEP1 Abs and EAMs in larger cohorts of RA patients to possibly confirm its role as biomarker for RA-ILD.

Dimensions

Altmetric

PlumX Metrics

Downloads

Download data is not yet available.
Published
2018-07-06
Info
Issue
Section
Articles
Keywords:
Rheumatoid arthritis.
Statistics
  • Abstract views: 1063

  • PDF: 401
How to Cite
Alunno, A., Bistoni, O., Pratesi, F., Topini, F., Puxeddu, I., Valentini, V., Cafaro, G., Bartoloni, E., Migliorini, P., & Gerli, R. (2018). Association between anti-citrullinated alpha enolase antibodies and clinical features in a cohort of patients with rheumatoid arthritis: a pilot study. Reumatismo, 70(2), 67-71. https://doi.org/10.4081/reumatismo.2018.1028

Most read articles by the same author(s)